Stockreport

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics [Yahoo! Finance]

Acurx Pharmaceuticals, Inc.  (ACXP) 
PDF Changes in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-trea [Read more]